Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TGM2 | P21980 | 5/20 | 0.40 |
| ▸ | F13A1 | P00488 | 3/20 | 0.39 |
| ▸ | TGM1 | P22735 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | USP5 | P45974 | 1/20 | 0.38 |
| ▸ | TGM6 | O95932 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741880 | 1.00 | UTS2R (0.44) | UTS2RSMN1; SMN2MAPTTGM2F13A1 | |
| SCHEMBL6093947 | 0.95 | SMN1; SMN2 (0.44) | UTS2RSMN1; SMN2MAPTTGM2F13A1 | |
| SCHEMBL6741630 | 0.94 | UTS2R (0.46) | UTS2RSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL6742625 | 0.87 | UTS2R (0.61) | UTS2R | |
| SCHEMBL6744780 | 0.87 | UTS2R (0.61) | UTS2R | |
| SCHEMBL6741280 | 0.87 | UTS2R (0.55) | UTS2RSMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL6741196 | 0.86 | UTS2R (0.48) | UTS2RSMN1; SMN2TGM2POLB | |
| SCHEMBL6741883 | 0.82 | UTS2R (0.53) | UTS2RSMN1; SMN2MAPTPKMHTT | |
| SCHEMBL6744737 | 0.82 | UTS2R (0.53) | UTS2RSMN1; SMN2MAPTPKMHTT | |
| SCHEMBL6094514 | 0.82 | HRH3 (0.40) | SMN1; SMN2MAPTTGM2LMNAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | UTS2R, PLAUR, SERPINE1 | UTS2R 1/4885SMN1; SMN2 2258/4885MAPT 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.